5:17PM 21. 2005

NOV 2 5 2005

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATEN	TING
REJECTION OVER A "PRIOR" PATENT	

Docket No.:

6687.US.01

			[(ABB1207P1650US)
Applicant(s):	Hong Yu et al.	Confirmation No.:	5110
Serial No.:	09/542,718	Filing Date:	04/04/2000
Group Art Unit:		Examiner:	D. Johannsen
invention:	Bela2 Adrenergic Polymorphism Detection		

The owner*, Abbott Laboratories, of 100% (One Hundred percent) Interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term prior patent No. 6,593,092 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shell be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for failure to pay a maintenance fee;

is held unenforceable:

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321:

has all claims canceled by a reexamination certificate:

is reissued; or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2, if appropriate.

1. . For submission on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

- The undersigned is an attorney of record.*
 - Terminal Disclaimer fee under 37 CFR 1.20(d) is enclosed in the amount of:

 \$\overline{\text{\infty}}\$\$ \$130,00 (large entity)

☐ \$ 65.00 (small entity)

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to 0 Deposit Account Number 23-0785. A duplicate copy of this sheet is enclosed.

Yasger, Reg. No. 37,477 Phone: (847) 938-3508

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER Citigroup Center, Suite 3800 500 West Madison Street

Chicago, Illinois 60661-2511

312/876-1800

* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assigned (owner) Form PTO/SB/96 may be used for making this certification. See MPEP \$324.

11/28/2005 DEMMANU1 00000047 09542718 -

01 FC:1814

130.00 OP



CERTIFICATE OF MAILING

I hereby certify that this Terminal Disclaimer To Obviate A Double Patenting Rejection Over A "Prior"

Patent, and any document referred to as being enclosed, is being deposited with the United States Postal

Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, P.O.

Box 1450, Alexandria, Virginia 22313-1450 on November 22, 2005.

Laura Czech